Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals
- 24 August 2009
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 23 (13) , 1707-1715
Abstract
Objectives: To determine if highly active antiretroviral therapy (HAART) with combination anti-hepatitis B virus (HBV) therapy compared to HAART with HBV monotherapy leads to greater HBV DNA suppression in an HIV/HBV coinfected cohort. Design: A cross-sectional analysis of 122 HIV/HBV coinfected patients from Australia and the United States. Methods: Univariate analysis and ordinal logistic regression were used to determine factors associated with an HBV DNA less than 100 IU/ml. Results: The majority of patients were on HAART (85%), had an HIV RNA less than 50 copies/ml, a median CD4 cell count of 438 cells/μl, and had prior or current lamivudine therapy (98%). The majority (89%) of those on HAART were on HBV-active drugs including 54% on tenofovir (TDF) with either lamivudine (LAM) or emtrictabine (FTC), 34% receiving LAM or FTC monotherapy, and 12% on TDF monotherapy. Only 4% of patients in the combination (TDF + LAM/FTC) group had HBV DNA greater than 20 000 IU/ml compared to 54% in the group on no HBV-active therapy, 31% in the LAM or FTC monotherapy group, and 30% in the TDF monotherapy group (P < 0.0001). In an ordinal logistic regression model, monotherapy with either TDF or LAM remained independently associated with higher HBV DNA. Conclusion: These data suggest that there may be an advantage to using TDF in combination with LAM or FTC in HIV/HBV coinfection, particularly in the setting of previous LAM experience. Continued prospective follow-up in this study will confirm whether the advantage is sustained longer-term.Keywords
This publication has 27 references indexed in Scilit:
- A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand†Hepatology, 2008
- SEQHEPB: A sequence analysis program and relational database system for chronic hepatitis BAntiviral Research, 2007
- Do HIV Care Providers Appropriately Manage Hepatitis B in Coinfected Patients Treated with Antiretroviral Therapy?Clinical Infectious Diseases, 2007
- Chronic hepatitis BHepatology, 2007
- Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis BHepatology, 2007
- Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfectionAIDS, 2006
- Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis B Extensively Exposed to Antiretroviral Therapy with Anti-HBV ActivityHIV Research & Clinical Practice, 2006
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Human Immunodeficiency Virus Type 1 Expressing the Lamivudine‐Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability In VitroThe Journal of Infectious Diseases, 1999
- THE MULTICENTER AIDS COHORT STUDY: RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTSAmerican Journal of Epidemiology, 1987